Patent ductus arteriosus medical therapy in term and older children

Jump to: navigation, search

Patent Ductus Arteriosus Microchapters

Home

Patient Information

Diagram

Overview

Anatomy

Historical Perspective

Pathophysiology

Causes

Differentiating Patent Ductus Arteriosus from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography

Other Imaging Findings

Treatment

Medical Therapy

Preterm Infants
Term and Older Children

Surgery

Primary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Patent ductus arteriosus medical therapy in term and older children On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Patent ductus arteriosus medical therapy in term and older children

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Patent ductus arteriosus medical therapy in term and older children

CDC on Patent ductus arteriosus medical therapy in term and older children

Patent ductus arteriosus medical therapy in term and older children in the news

Blogs on Patent ductus arteriosus medical therapy in term and older children

Directions to Hospitals Treating Type page name here

Risk calculators and risk factors for Patent ductus arteriosus medical therapy in term and older children

Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Priyamvada Singh, M.B.B.S. [2], Cafer Zorkun, M.D., Ph.D. [3]; Assistant Editor-In-Chief: Kristin Feeney, B.S. [4]

Overview

In term infants and older patients, the Prostaglandin E2 inhibitors (indomethacin and ibuprofen) have not shown to be effective. This is so because the ductus in premature baby is different histologicaly from in older patients. As a result, pharmacologic therapy is only used routinely in preterm infants.

2008 ACC/AHA Guidelines for the Management of Adults with Congenital Heart Disease (DO NOT EDIT)[1]

Recommendations for Medical Therapy (DO NOT EDIT)[1]

Class I
"1. Routine follow-up is recommended for patients with a small PDA without evidence of left-sided heart volume overload. Follow-up is recommended every 3 to 5 years for patients with a small PDA without evidence of left-heart volume overload.(Level of Evidence: C) "
Class III (Harm)
"1. Endocarditis prophylaxis is not recommended for those with a repaired PDA without residual shunt. (Level of Evidence: C) "

References


Linked-in.jpg